Advertisement
"I am very pleased to welcome Reinaldo to our Board of Directors" saidJoseph Galli, Haemacure's Chairman of the Board and Chief Executive Officer."His experience and know-how in the biopharmaceutical industry and assetmanagement field will certainly be beneficial to Haemacure's continued growth,development and operations for years to come" concluded Mr. Galli.
Advertisement
About Reinaldo M. Diaz
Mr. Diaz has over 25 years of experience in the biopharmaceuticalindustry. He currently serves as a Managing Director of Celtic PharmaManagement, L.P. a global equity firm focused on the pharmaceutical industry.Prior to joining Celtic Pharma, Mr. Diaz was Managing Member and Co-Founder ofD&A Capital Management, LLC ("D&A Capital"), a firm focused on assetmanagement and providing advisory services to companies in the healthcaresector, particularly biopharmaceutical companies. From 1993 to 1996, Reinaldowas Managing Director and Head of the Healthcare group at Schroder Wertheim &Co., Inc. In that capacity, he was responsible for establishing and expandingSchroder Wertheim's investment banking presence in the healthcare industry.From 1981 to 1993, Reinaldo was with PaineWebber, Inc. During his tenure atPaineWebber, he was a key member of the PaineWebber Healthcare InvestmentBanking Group and of PaineWebber Development Corporation. He became Presidentof PaineWebber Development Corporation in 1990, having been a managingdirector prior to that time.
"I am pleased to join Haemacure's Board of Directors and look forward toworking with Joseph Galli, Haemacure's management team and other board membersto help Haemacure achieve its product development and commercial goals," saidMr. Diaz.
About Haemacure
Haemacure Corporation is a specialty biotherapeutics company developinghigh-value human plasma-derived protein products for commercialization.Haemacure's research and development effort is driven by its proprietaryplasma protein extraction technology to develop next-generation products,including surgical hemostats. Haemacure's lead product candidate,Hemaseel(R)HMN, is a fibrin sealant planned to enter pivotal Phase II/PhaseIII clinical trials during the first quarter of 2009. Haemacure's secondproduct candidate is thrombin, a component of its fibrin sealant, now inpreclinical stage. Follow-on development will focus on surgical hemostats,wound healing, adhesion prevention, regenerative medecine, drug delivery andcombination with biomaterials. Haemacure has discovered eleven additionalspecialty proteins and enzymes in one if its two plasma fractions and seeks toadvance these proteins and enzymes through partnerships with pharmaceuticaland biotechnology companies. Haemacure operates offices in Sarasota, Floridathrough a wholly-owned subsidiary. The Corporation is traded under stocksymbol HAE on the TSX.
SOURCE Haemacure Corporation
